Tag:
Prolia
Latest Headlines
Latest Headlines
Hated German price formula to be applied to Pradaxa, Prolia, other drugs
Drugmakers, livid with German pricing gatekeepers for turning down so many new drugs, now face a strategy that is sure to ratchet up their anger to the boiling point.
Merck's osteoporosis drug 'odana' clinches promising PhIII data
Merck says it nailed the positive Phase III data it needs to gain an approval on the late-stage osteoporosis drug odanacatib, allowing investigators to start wrapping up the big global study and accelerating the timeline on the potential blockbuster.
Amgen's new meds beat estimates as anemia drugs slip
Amgen's ( $AMGN ) anemia drugs faltered again in the fourth quarter with sales declining 15% on Aranesp and 18% on Epogen . New bone drugs Xgeva and Prolia beat analyst estimates for their first full
Amgen's Prolia wins new uses, performs in study
It's a good news-good news day for Amgen ( $AMGN ). The company's new bone drug is gathering indications--and potential sales--like a snowball rolling downhill. Under the name Prolia, the drug won FDA
AZ to co-promote Amgen bone drug in Japan
AstraZeneca has signed on to promote Amgen's bone drug denosumab in Japan. The deal with Daiichi Sankyo, which holds the Japanese rights to the drug, gives AZ a promising new treatment to sell in a
NICE gives thumbs-up to Amgen bone drug
The U.K.'s cost-effectiveness watchdog has approved Amgen's (AMGN) osteoporosis drug Prolia (denosumab) for routine use by the National Health Service in postmenopausal patients who are at increased
Amgen's Prolia wins priority review for cancer use
Amgen's ( NASDAQ: AMGN ) great new hope--the bone drug Prolia --won priority review at the FDA for a new, potentially lucrative cancer indication. The use: cancer that has spread to bone. The upshot: an
Amgen bone drug gets NICE thumbs up
It's another victory for Amgen with its new drug Prolia. The U.K.'s cost-effectiveness watchdog has recommended use of the bone treatment by the National Health Service, in women at risk of fractures
ASCO spotlights new tricks for existing drugs
Much of the focus at the annual American Society of Clinical Oncology meeting is on experimental meds: What pipeline remedies are proving most effective for the companies testing them? But existing
Who's vulnerable to Amgen's new bone drug?
We know who stands to win off the early FDA approval of the bone drug Prolia, and that's Amgen ( NASDAQ: AMGN ). But who stands to lose? A variety of drugmakers sell drugs for osteoporosis, the
